Effect of epirubicin and tamowifen on labelling index in FM3A cells
Yıl: 2002 Cilt: 1 Sayı: 2 Sayfa Aralığı: 81 - 85 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022
Effect of epirubicin and tamowifen on labelling index in FM3A cells
Öz: C3H fare meme karsinomu kökenli, RPMI 1640+%10 FBS içinde süspansiyon olarak kültüre edilmiş FM3A hücre soyu, son yıllarda doku kültürü çalışmalarında kullanılmaktadır. Bu çalışmada, FM3A hücreleri üzerine epirubisin, tamoksifen ve epirubisin+tamoksifenin in vitro dozları uygulanarak, işaretlenme indeksindeki değişimler incelenmiştir. Bulgular, epirubisin ve tamoksifen uygulamaları ile S fazındaki hücre yüzdelerinin düştüğünü, epirubisin ve tamoksifenin kombine uygulanmasının ise bu açıdan daha etkili ve istatistiksel olarak anlamlı (p<0.01) olduğunu göstermişlerdir.
Anahtar Kelime: Konular:
FM3A hücrelerinin işaretlenme indeksi üzerine epirubisin ve tamoksifenin etkisi
Öz: C3H mouse mammary carsinoma-derived FM3A cell line grown in RPMI 1640+10%FBS medium as suspension culture have been used in tissue culture studies in recent years. Changes in labelling index were examined in the present study, applying in vitro doses of epirubicin, tamoxifen and epirubicin+tamoxifen to FM3A cells. The findings reveal that treatments of epirubicin and tamoxifen lower the percentage of the cells at S phase, while combined treatment of epirubicin and tamoxifen gives more successful results, being statistically significant (p<0.01).
Anahtar Kelime: Konular:
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- Aglietta M, Monzeglio C, Pasquino P, Carnino F, Stern AC and Gavosto F. Short-term administration of granulocyte-macrophage colony stimulating factor decreases hematopoietic toxicity of cytostatic drugs. Cancer. 72: 2970-2973, 1993.
- Beatson GT. On the treatment of inoperable cases of carsinoma of mammal: Suggestions for a new method of treatment, with illustrative cases. Lancet. 2: 104- 107, 1896.
- Boccardo F, Rubagotti A, Bruzzi P, Cappellini M, Isola G, Nenci I, Piffanelli A, Scanni A, Sismondi P and Santi L. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor- positive breast cancer patients: Results of a multicentric Italian study. J Clin Oncol. 8: 1310- 1320, 1990.
- Cantoni O, Sestili P, Cattabeni F, Geroni C and Giuliani F. Comparative effects of doxorubicin and 4´- epidoxorubicin on nucleic acid metabolism and cytotoxicity in a human tumour cell line. Cancer Chemotherapy and Pharmacology. 27: 47-51, 1990.
- Clarke RB, Laidlaw IJ, Jones LJ, Howell A and Anderson E. Effect of tamoxifen on Ki67 labelling index in human breast tumours and it’s relationship to oestrogen progesterone receptor status. Br J Cancer. 67: 606- 11, 1993.
- Cuzick J and Baum M. Tamoxifen and contralateral breast cancer. Lancet (i). 282, 1985.
- Di marco A. Epirubicin: Mechanism of action at the cellular level. In: Advances in Anthracycline Chemotherapy. Epirubicin. Bonadonna G (Ed). Masson, Milano - Italia. 41-47, 1984.
- Douglas KT. Anticancer drugs, DNA-intercalation and free radical attack. Chemistry and Industry. 766-771, 1984.
- Greg L, Faulds P and Faulds D. Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy. Drugs. 45: 788-856, 1993.
- Gullino PM, Pettigrew HN and Grantham FH. N- Nitrosomethylurea as mammary gland carcinogen in rats. J Natl Cancer Inst. 54: 401-414, 1975.
- Huggins SC, Grand LC and Brillantes FP. Mammary cancer, induced by a single feeding of polynuclear hydrocarbons and their suppression. Nature. 189: 204- 207, 1962.
- Lippman M and Huff KA. Demonstration of androgen and estrogen receptors in a human breast cancer using a new protamine sulfate assay. Cancer. 38: 868-874, 1976.
- Mc Guire WL, Horwitz KB, Zava DT, Garola RE and Chamness GC. Hormones in breast cancer: Update 1978. Metabolism. 27: 487-501, 1978.
- Mouridsen H, Palshof T, Paterson J and Battersby L. Tamoxifen in advanced breast cancer. Cancer Treat Rev. 5: 131-141, 1978.
- Murphy B and Muss HB. Hormonal therapy of breast cancer: State of the art. Oncology. 11, Supp. 4: 7-13, 1997.
- Muss HB. Endocrine therapy for advanced breast cancer: A review. Breast Cancer Res Treat. 21: 15-26, 1992.
- Raynaud JP, Martin PM, Bouton MM and Ojasoo T. 11-b- mehoxy-17-ethynyl-1,3,5 (10)-estratriene-3, 17-b-diol (Moxestrol), a tag for estrogen receptor binding sites in human tissues. Cancer Res. 38: 3044-3050, 1978.
- Robert J and Gianni L. Pharmacokinetics and metabolism of anthracyclines. Cancer Surv. 17: 219-252, 1993.
- Rose C, Thorpe SM, Lober J, Daehnfeldt JL, Palshof T and Mouridsen HT. Therapeutic effect of tamoxifen related to estrogen receptor level. In: Recent Results in Cancer Research. Henningsen B, Linder F and Steichele C (Eds). Vol. 71 Berlin, Springer Verlag. 134-141, 1980.
- Sinha BK and Porti PM. Anthracyclines, cancer chemotherapy. Biol Response Modif. 11: 45-57, 1990.
- Sipila PE, Wiebe VJ, Hubbard GB, Koester SK, Emshoff VD, Maenpaa JU, Wurz GT, Seymour RC and De Gregorio MW. Prolonged tamoxifen exposure selects a breast cancer cell clone that is stable in vitro and in vivo. Eur J Cancer. 29 A: 2138-2144, 1993.
- Skladanowski A and Konopa J. Interstrand DNA crosslinking induced by anthracyclines in tumour cells. Biochem Pharmacol. 47: 2269-2278, 1994.
| APA | Topçul M, ARICAN Ö, ERENSOY N, ÖZALPAN A (2002). Effect of epirubicin and tamowifen on labelling index in FM3A cells. , 81 - 85. |
| Chicago | Topçul Mehmet Rıfkı,ARICAN Özcan Gül,ERENSOY Nevin,ÖZALPAN Atilla Effect of epirubicin and tamowifen on labelling index in FM3A cells. (2002): 81 - 85. |
| MLA | Topçul Mehmet Rıfkı,ARICAN Özcan Gül,ERENSOY Nevin,ÖZALPAN Atilla Effect of epirubicin and tamowifen on labelling index in FM3A cells. , 2002, ss.81 - 85. |
| AMA | Topçul M,ARICAN Ö,ERENSOY N,ÖZALPAN A Effect of epirubicin and tamowifen on labelling index in FM3A cells. . 2002; 81 - 85. |
| Vancouver | Topçul M,ARICAN Ö,ERENSOY N,ÖZALPAN A Effect of epirubicin and tamowifen on labelling index in FM3A cells. . 2002; 81 - 85. |
| IEEE | Topçul M,ARICAN Ö,ERENSOY N,ÖZALPAN A "Effect of epirubicin and tamowifen on labelling index in FM3A cells." , ss.81 - 85, 2002. |
| ISNAD | Topçul, Mehmet Rıfkı vd. "Effect of epirubicin and tamowifen on labelling index in FM3A cells". (2002), 81-85. |
| APA | Topçul M, ARICAN Ö, ERENSOY N, ÖZALPAN A (2002). Effect of epirubicin and tamowifen on labelling index in FM3A cells. Journal of Cell and Molecular Biology, 1(2), 81 - 85. |
| Chicago | Topçul Mehmet Rıfkı,ARICAN Özcan Gül,ERENSOY Nevin,ÖZALPAN Atilla Effect of epirubicin and tamowifen on labelling index in FM3A cells. Journal of Cell and Molecular Biology 1, no.2 (2002): 81 - 85. |
| MLA | Topçul Mehmet Rıfkı,ARICAN Özcan Gül,ERENSOY Nevin,ÖZALPAN Atilla Effect of epirubicin and tamowifen on labelling index in FM3A cells. Journal of Cell and Molecular Biology, vol.1, no.2, 2002, ss.81 - 85. |
| AMA | Topçul M,ARICAN Ö,ERENSOY N,ÖZALPAN A Effect of epirubicin and tamowifen on labelling index in FM3A cells. Journal of Cell and Molecular Biology. 2002; 1(2): 81 - 85. |
| Vancouver | Topçul M,ARICAN Ö,ERENSOY N,ÖZALPAN A Effect of epirubicin and tamowifen on labelling index in FM3A cells. Journal of Cell and Molecular Biology. 2002; 1(2): 81 - 85. |
| IEEE | Topçul M,ARICAN Ö,ERENSOY N,ÖZALPAN A "Effect of epirubicin and tamowifen on labelling index in FM3A cells." Journal of Cell and Molecular Biology, 1, ss.81 - 85, 2002. |
| ISNAD | Topçul, Mehmet Rıfkı vd. "Effect of epirubicin and tamowifen on labelling index in FM3A cells". Journal of Cell and Molecular Biology 1/2 (2002), 81-85. |
